Which has stronger earnings and valuation, ATHE or CLRB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$15.88M N/A N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is ATHE or CLRB more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Cellectar Biosciences N/A -185.35% -115.42%

Does the media prefer ATHE or CLRB?

In the previous week, Cellectar Biosciences had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Cellectar Biosciences and 3 mentions for Alterity Therapeutics. Cellectar Biosciences' average media sentiment score of 0.68 beat Alterity Therapeutics' score of -0.24 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ELOX or CLRB more profitable?

Eloxx Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eloxx Pharmaceuticals N/A N/A N/A Cellectar Biosciences N/A -185.35% -115.42%

Does the media favor ELOX or CLRB?

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 6 mentions for Eloxx Pharmaceuticals and 5 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.68 beat Eloxx Pharmaceuticals' score of 0.13 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TLPH or CLRB more profitable?

Talphera's return on equity of -87.28% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Cellectar Biosciences N/A -185.35% -115.42%

Does the media favor TLPH or CLRB?

In the previous week, Cellectar Biosciences had 4 more articles in the media than Talphera. MarketBeat recorded 5 mentions for Cellectar Biosciences and 1 mentions for Talphera. Cellectar Biosciences' average media sentiment score of 0.68 beat Talphera's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CLRB or ZYBT?

Cellectar Biosciences currently has a consensus target price of $11.00, indicating a potential upside of 517.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CLRB or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Cellectar Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A Zhengye Biotechnology $116.36M 0.51 -$9.98M N/A N/A

Is CLRB or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Zhengye Biotechnology N/A N/A N/A

Does the media refer more to CLRB or HRTX?

In the previous week, Cellectar Biosciences had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for Cellectar Biosciences and 3 mentions for Heron Therapeutics. Cellectar Biosciences' average media sentiment score of 0.68 beat Heron Therapeutics' score of 0.36 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cellectar Biosciences (CLRB) Competitors

$1.78 -0.09 (-4.81%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.84 +0.06 (+3.37%)

As of 10/2/2026 07:30 PM Eastern

Compare

CLRB vs. ATHE, ELOX, TLPH, ZYBT, and HRTX

Should you buy Cellectar Biosciences stock or one of its competitors? Cellectar Biosciences's main competitors and comparable companies include Alterity Therapeutics (ATHE), Eloxx Pharmaceuticals (ELOX), Talphera (TLPH), Zhengye Biotechnology (ZYBT), and Heron Therapeutics (HRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cellectar Biosciences compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

Alterity Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 189.86%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 517.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Alterity Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Alterity Therapeutics' return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Cellectar Biosciences	N/A	-185.35%	-115.42%

In the previous week, Cellectar Biosciences had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 5 mentions for Cellectar Biosciences and 3 mentions for Alterity Therapeutics. Cellectar Biosciences' average media sentiment score of 0.68 beat Alterity Therapeutics' score of -0.24 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cellectar Biosciences beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Cellectar Biosciences compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 6 mentions for Eloxx Pharmaceuticals and 5 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.68 beat Eloxx Pharmaceuticals' score of 0.13 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Eloxx Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	9.85	-$5.99M	-$1.54	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

Eloxx Pharmaceuticals has a beta of -1960.42, suggesting that its stock price is 196,142% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Eloxx Pharmaceuticals' return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Cellectar Biosciences	N/A	-185.35%	-115.42%

Eloxx Pharmaceuticals currently has a consensus target price of $38.33, suggesting a potential upside of 147.15%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 517.98%. Given Cellectar Biosciences' higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Eloxx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Eloxx Pharmaceuticals beats Cellectar Biosciences on 9 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Talphera?

Talphera (NASDAQ:TLPH) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Talphera's return on equity of -87.28% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Cellectar Biosciences	N/A	-185.35%	-115.42%

In the previous week, Cellectar Biosciences had 4 more articles in the media than Talphera. MarketBeat recorded 5 mentions for Cellectar Biosciences and 1 mentions for Talphera. Cellectar Biosciences' average media sentiment score of 0.68 beat Talphera's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Talphera has higher revenue and earnings than Cellectar Biosciences. Talphera is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$30K	1,955.28	-$14.29M	-$0.27	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

37.7% of Talphera shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 3.5% of Talphera shares are held by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Talphera presently has a consensus target price of $3.00, indicating a potential upside of 165.49%. Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 517.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Talphera has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

Summary

Talphera beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Zhengye Biotechnology?

Cellectar Biosciences (NASDAQ:CLRB) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Cellectar Biosciences currently has a consensus target price of $11.00, indicating a potential upside of 517.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cellectar Biosciences has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.31, meaning that its share price is 331% less volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Cellectar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Zhengye Biotechnology	$116.36M	0.51	-$9.98M	N/A	N/A

In the previous week, Cellectar Biosciences had 5 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Cellectar Biosciences and 0 mentions for Zhengye Biotechnology. Cellectar Biosciences' average media sentiment score of 0.68 beat Zhengye Biotechnology's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
Zhengye Biotechnology	Neutral

Zhengye Biotechnology's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Cellectar Biosciences beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to Heron Therapeutics?

Cellectar Biosciences (NASDAQ:CLRB) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 5 mentions for Cellectar Biosciences and 3 mentions for Heron Therapeutics. Cellectar Biosciences' average media sentiment score of 0.68 beat Heron Therapeutics' score of 0.36 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectar Biosciences has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Cellectar Biosciences' return on equity of -185.35% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Heron Therapeutics has higher revenue and earnings than Cellectar Biosciences. Heron Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Heron Therapeutics	$154.90M	0.43	-$20.19M	-$0.19	N/A

Cellectar Biosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Cellectar Biosciences currently has a consensus target price of $11.00, indicating a potential upside of 517.98%. Heron Therapeutics has a consensus target price of $2.00, indicating a potential upside of 475.37%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cellectar Biosciences is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cellectar Biosciences beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.82M	$12.24B	$7.16B	$13.28B
Dividend Yield	N/A	2.64%	2.54%	17.32%
P/E Ratio	-0.46	799.70	275.66	26.04
Price / Sales	N/A	752.91	608.92	91.72
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	0.94	10.46	10.93	6.31
Net Income	-$21.79M	$2.84B	$3.51B	$362.16M
7 Day Performance	-1.11%	-1.56%	-2.00%	-1.66%
1 Month Performance	-24.89%	-5.58%	-6.19%	-4.68%
1 Year Performance	-69.20%	-2.40%	8.03%	1.57%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	2.9368 of 5 stars	$1.78 -4.8%	$11.00 +518.0%	-69.2%	$16.82M	N/A	N/A	11	Gap Up
ATHE Alterity Therapeutics	3.5988 of 5 stars	$3.66 +4.6%	$10.00 +173.2%	-18.8%	$66.36M	N/A	N/A	11
ELOX Eloxx Pharmaceuticals	2.9622 of 5 stars	$15.42 +2.8%	$38.33 +148.6%	N/A	$62.30M	$6.36M	N/A	7	Short Interest Increase
TLPH Talphera	1.4938 of 5 stars	$1.17 -1.7%	$3.00 +156.4%	+18.9%	$60.74M	$30K	N/A	12
ZYBT Zhengye Biotechnology	N/A	$1.24 -4.6%	N/A	-53.7%	$58.76M	$16.64M	N/A	269

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. ATHE, ELOX, TLPH, ZYBT, and HRTX

How does Cellectar Biosciences compare to Alterity Therapeutics?

Summary

How does Cellectar Biosciences compare to Eloxx Pharmaceuticals?

Summary

How does Cellectar Biosciences compare to Talphera?

Summary

How does Cellectar Biosciences compare to Zhengye Biotechnology?

Summary

How does Cellectar Biosciences compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. ATHE, ELOX, TLPH, ZYBT, and HRTX

How does Cellectar Biosciences compare to Alterity Therapeutics?

Do analysts rate ATHE or CLRB?

Which has more risk and volatility, ATHE or CLRB?

Which has stronger earnings and valuation, ATHE or CLRB?

Is ATHE or CLRB more profitable?

Does the media prefer ATHE or CLRB?

Do institutionals and insiders have more ownership in ATHE or CLRB?

Summary

How does Cellectar Biosciences compare to Eloxx Pharmaceuticals?

Does the media favor ELOX or CLRB?

Do insiders & institutionals have more ownership in ELOX or CLRB?

Which has higher earnings & valuation, ELOX or CLRB?

Which has more risk & volatility, ELOX or CLRB?

Is ELOX or CLRB more profitable?

Do analysts rate ELOX or CLRB?

Summary

How does Cellectar Biosciences compare to Talphera?

Is TLPH or CLRB more profitable?

Does the media favor TLPH or CLRB?

Which has stronger valuation and earnings, TLPH or CLRB?

Do insiders & institutionals hold more shares of TLPH or CLRB?

Do analysts prefer TLPH or CLRB?

Which has more risk and volatility, TLPH or CLRB?

Summary

How does Cellectar Biosciences compare to Zhengye Biotechnology?

Do analysts recommend CLRB or ZYBT?

Do institutionals & insiders believe in CLRB or ZYBT?

Which has more volatility and risk, CLRB or ZYBT?

Which has preferable valuation and earnings, CLRB or ZYBT?

Does the media refer more to CLRB or ZYBT?

Is CLRB or ZYBT more profitable?

Summary

How does Cellectar Biosciences compare to Heron Therapeutics?

Do insiders and institutionals believe in CLRB or HRTX?

Does the media refer more to CLRB or HRTX?

Is CLRB or HRTX more profitable?

Which has higher earnings and valuation, CLRB or HRTX?

Which has more volatility & risk, CLRB or HRTX?

Do analysts recommend CLRB or HRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools